Company intelligence / Profile preview

Frantz Viral Therapeutics

Mentor, Ohio, United Statesfrantzviraltherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

The company's lead asset, a proprietary artesunate-based topical therapy, has completed Phase I/IIa studies showing good tolerability and potential efficacy as a non-surgical treatment option for HPV-associated high-grade squamous intraepithelial lesions in the cervix, anus, and vulva/vagina. Ongoing Phase II trials are further evaluating safety and efficacy[5][7].

Therapeutic areas: Oncology
Modalities: Small moleculesTopical formulations
Industry: Biotech

Drug pipeline

1 asset

artesunate

Phase 2

Indications: HPV-induced neoplasia, Cervical cancer, Vulvar cancer, Anal cancer

Beyond the preview

Go deeper on Frantz Viral Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frantz Viral Therapeutics.

Explore the full profile